Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis-a pharmacokinetic study

Nephrology Dialysis Transplantation

Volumn 25, Issue 5, 2010, Pages 1537-1541

  Kielstein, Jan T ^a   Eugbers, Catrin ^a   Bode Boeger, Stefanie M ^b   Martens Lobenhoffer, Jens ^b   Haller, Hermann ^a   Joukhadar, Christian ^c,d   Traunmüller, Friederike ^c   Knitsch, Wolfgang ^a   Hafer, Carsten ^a   Burkhardt, Olaf ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c JandP Medical Research Ltd   (Austria)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Acute kidney injury; Daptomycin; Extended dialysis; Pharmacokinetics

Indexed keywords

DAPTOMYCIN; POLYSULFONE;

ABSENCE OF SIDE EFFECTS; ACUTE DISEASE; ADULT; AGED; ANURIA; ARTICLE; ARTIFICIAL KIDNEY; BLOOD FLOW; CLINICAL ARTICLE; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DIALYSATE; DIALYSIS; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG HALF LIFE; FEMALE; HUMAN; INFECTION; INTENSIVE CARE UNIT; KIDNEY INJURY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK; SINGLE DRUG DOSE; TERTIARY HEALTH CARE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; FEMALE; HUMANS; INTENSIVE CARE UNITS; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 77951687516     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp704     Document Type: Article

References (21)

1. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005; 294: 813-818 (Pubitemid 41175724)
2. Dvorchik BH, Brazier D, DeBruin MF, et al. Daptomycin pharmaco-kinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003; 47: 1318-1323 (Pubitemid 36368592)
3. Dvorchik B, Arbeit RD, Chung J, et al. Population pharmacoki-netics of daptomycin. Antimicrob Agents Chemother 2004; 48: 2799-2807
4. Huen SC, Hall I, Topal J, et al. Successful use of intraperitoneal dap-tomycin in the treatment of vancomycin-resistant enterococcus peritonitis. Am J Kidney Dis 2009; 54: 538-541
5. LaPlante KL, Mermel LA. In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. Nephrol Dial Transplant 2007; 22: 2239-2246
6. Burkhardt O, Joukhadar C, Traunmuller F, et al. Elimination of daptomycin in a patient with acute renal failure undergoing extended daily dialysis. J Antimicrob Chemother 2008; 61: 224-225
7. Faulhaber-Walter R, Hafer C, Jahr N, et al. The Hannover Dialysis Outcome study: comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit. Nephrol Dial Transplant 2009; 24: 2179-2186
8. Fliser D, Kielstein JT. Technology Insight: treatment of renal failure in the intensive care unit with extended dialysis. Nat Clin Pract Nephrol 2006; 2: 32-39
9. Kumar VA, Craig M, Depner TA, et al. Extended daily dialysis: a new approach to renal replacement for acute renal failure in the intensive care unit. Am J Kidney Dis 2000; 36: 294-300 (Pubitemid 30485837)
10. Marshall MR, Golper TA, Shaver MJ, et al. Sustained low-efficiency dialysis for critically ill patients requiring renal replacement therapy. Kidney Int 2001; 60: 777-785 (Pubitemid 32678922)
11. Mueller BA, Pasko DA, Sowinski KM. Higher renal replacement therapy dose delivery influences on drug therapy. Artif Organs 2003; 27: 808-814 (Pubitemid 37108621)
12. Burkhardt O, Hafer C, Langhoff A, et al. Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis. Nephrol Dial Transplant 2009; 24: 267-271
13. Czock D, Husig-Linde C, Langhoff A, et al. Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. Clin J Am Soc Nephrol 2006; 1: 1263-1268
14. Fiaccadori E, Maggiore U, Rotelli C, et al. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit Care Med 2004; 32: 2437-2442 (Pubitemid 39648225)
15. Kielstein JT, Czock D, Schopke T, et al. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med 2006; 34: 51-56 (Pubitemid 43032379)
16. Kielstein JT, Lorenzen J, Kaever V, et al. Risk of underdosing of ampicillin/sulbactam in patients with acute kidney injury undergoing extended daily dialysis-a single case. Nephrol Dial Transplant 2009; 24: 2283-2285
17. Eloot S, Van Biesen W, Dhondt A, et al. Impact of hemodialysis duration on the removal of uremic retention solutes. Kidney Int 2008; 73: 765-770 (Pubitemid 351323256)
18. Dhondt A, Eloot S, Wachter DD, et al. Dialysate partitioning in the Genius batch hemodialysis system: effect of temperature and solute concentration. Kidney Int 2005; 67: 2470-2476 (Pubitemid 41623412)
19. Martens-Lobenhoffer J, Kielstein JT, Oye C, et al. Validated high performance liquid chromatography-UV detection method for the determination of daptomycin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 15: 546-550
20. Churchwell MD, Pasko DA, Mueller BA. Daptomycin clearance during modeled continuous renal replacement therapy. Blood Purif 2006; 24: 548-554 (Pubitemid 46030098)
21. Palevsky PM, Zhang JH, O'Connor TZ, et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008; 359: 7-20 (Pubitemid 351931092)